BIOVECTRA signs service agreement with Acuitas Therapeutics for unique lipid nanoparticle (LNP) delivery system used in manufacturing mRNA-based therapies Post author: Post published:October 6, 2023 Post category:uncategorized BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service. You Might Also Like Cannabis use may quadruple the risk of developing diabetes September 15, 2025 Microbial generalists form planet-wide networks across ecosystems February 10, 2026 Research reveals undisclosed active ingredients in retail mushroom products September 13, 2025